Philip Home

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · The Lancet · 2009 · 1.4K citations

Medicine, Pharmacology, Pharmacotherapy +17

Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis

Philip Home, Stuart Pocock, Henning Beck‐Nielsen et al. · New England Journal of Medicine · 2007 · 763 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

Kjeld Hermansen, Melanie J. Davies, Tadeusz Dereziński et al. · Diabetes Care · 2006 · 631 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Julio Rosenstock, Melanie J. Davies, Philip Home et al. · Diabetologia · 2008 · 447 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease

Latika Sibal, Sharad Agarwal, Philip Home et al. · Current Cardiology Reviews · 2010 · 430 citations · Full text

Veterinary Medicine, Molecular Medicine, Pharmacology +16